Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

Parkinson Disease Clinical Trial

Official title: Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

Status Active, not recruiting

Clinical Trial Summary

This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain linked to visuospatial cognitive impairment in PD.

Clinical Trial Description

This study is a proof-of-concept Parkinson disease trial aimed at delaying visuospatial cognitive decline, an important component of Parkinson dementia. In Parkinson disease, low-range cortical Abeta plaque levels associate with serotonin terminal losses. Multicenter Parkinson disease observational findings show that selective serotonin reuptake inhibitors (SSRIs) associate with lower dementia conversion risk and different cerebrospinal fluid Abeta-42 levels. This study aims to test the hypothesis that citalopram use in Parkinson disease will reduce visuospatial cortex Abeta plaque accrual, leading to an amelioration of longitudinal visuospatial cognitive decline linked to Parkinsonian dementia. The study will test this hypothesis in a randomized placebo-controlled trial of citalopram 20mg daily over 26 months in Parkinson disease subjects (age ≥65) without depression (n=58). ;

Related Conditions & MeSH terms

• Parkinson Disease

• NCT number: NCT04497168
• Study type: Interventional
• Source: University of Michigan
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: April 1, 2021
• Completion date: March 1, 2026